Friends
I just posted my review of some pretty promising data on ABT-199 in difficult to treat patients with F refractory or del 17p disease.
Our future is getting more and more interesting.
Brian
ASCO 2013: ABT-199 in relapsed and refractory ... - CLL Support
ASCO 2013: ABT-199 in relapsed and refractory disease
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
minimal residual disease (uMRD) and complete responses (CRs) in patients with relapsed/refractory...
CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)
-on-the-fda-approval-of-liso-cel-in-relapsed-refractory-cll-sll
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
is ongoing and we look forward to seeing more data in the future.
More here:...
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
State University.
36 to 45 patients are planned to be enrolled.\\"
More:...
Related Posts
- Dr Sharman provides an update on an NIH CAR-T trial for relapsed/refractory DBLC
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
- Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)
Are UTI's more common while on Imbruvica?
Is BM transplant becoming more popular?
